ドルゾラミド塩酸塩

It is a carbonic anhydrase inhibitor (CAI) with actions similar to those of acetazolamide. It is used as 2% drops for topical treatment to lower intraocular pressure or glaucoma, either alone or in conjunction with a topical beta-blocker or prostaglandin analogue.

At the date of the last update we did not find any published data on its excretion in breast milk.

One infant, whose mother was treated with dorzolamide, timolol, dipivifrine, brimonidine, and acetazolamide, was breastfed for several months from birth and did not present any clinical problems. ^{(Johnson 2001)}

Dorzolamide plasma concentration is low and generally below detection limits ^{(AEMPS 2021, Purdue 2016)}. For this reason and because it is usually used as a topical treatment its presence in mother’s milk is unlikely. Like most ophthalmologic compounds for topical use, a low dose and poor absorption make it compatible with breastfeeding.

Systemic absorption should be minimized by pressing the tear duct (inner corner of the eye) with the finger for 1 to 2 minutes and administering the dose immediately after breastfeeding. ^{(Belkin 2020, Blumen 2020, Méndez 2012)}

Several medical societies and expert authors consider the use of CAI to be safe during breastfeeding. ^{(Blumen 2020)}